• CBD in Orofacial Inflammatory Pain: Mechanisms

  2026-10-06

  A 2026 Brain Research Bulletin study examined how cannabidiol (CBD) affects both nociception and pain-related emotional deficits in mouse models. Its main contribution is an integrated analysis linking peripheral CB2-associated anti-inflammatory effects with central CB1-associated changes in pain processing, cognition, and serotonin activity.

• Rocilinostat (ACY-1215): Evidence Beyond Selectivity

  2026-10-06

  Rocilinostat and ACY-1215 are examined through an evidence-first lens spanning HDAC6 biology, multiple myeloma, and primary cilia. This article distinguishes established anticancer findings from the open questions raised by SMPD4 research in neurodevelopment.

• Dinaciclib (SCH727965): Evidence and Limits

  2026-10-05

  Dinaciclib, also known as SCH727965, is a multi-CDK research compound linked to cell-cycle control, Rb phosphorylation, and apoptosis-related readouts. The strongest supplied evidence supports oncology-focused pathway studies and mouse xenograft research, while direct effects on embryonic tissue boundaries remain unestablished.

• Palonosetron and Chemotherapy-Induced Nausea

  2026-10-05

  Ruhlmann and Herrstedt review palonosetron as a long-acting 5-HT3 receptor antagonist and assess whether its distinctive pharmacology translates into clinically meaningful control of chemotherapy-induced nausea and vomiting. The article’s main value is its evidence-focused comparison of palonosetron with earlier agents, while also clarifying the persistent challenges of delayed emesis and inadequately studied nausea.

• Deep Learning Maps Cardiotoxicity in iPSC-CMs

  2026-10-04

  Grafton et al. developed a high-content imaging strategy that uses deep learning to identify cardiotoxic phenotypes in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The study shows how a single-parameter phenotype score can support early drug-discovery triage, while also emphasizing that in vitro signals require orthogonal and translational validation.

• Aclacinomycin A: rDNA Stress and Apoptosis

  2026-10-03

  Aclacinomycin A, also called Aclarubicin, is an anthracycline research compound described as a dual topoisomerase inhibitor and apoptosis inducer. Current evidence supports a mechanistic link between topological stress, persistent ribosomal-DNA lesions, and PML-nucleolar associations, but the cited rDNA study did not directly test Aclacinomycin A.

• Flubendazole for Autophagy Research Workflows

  2026-10-02

  Flubendazole provides a practical DMSO-based entry point for probing autophagy signaling pathway changes in cell models, while its use in fibrosis-related metabolism studies requires careful mechanistic separation. This workflow connects compound handling, flux-aware assay design, and troubleshooting to the glutamine-metabolism findings reported in hepatic stellate cells.

• FTO–FOXO1–m6A Control of ADSC Osteogenesis

  2026-10-01

  Wang et al. identify an FTO–FOXO1–RUNX2/PPARG axis through which m6A regulation shapes adipose-derived stem cell osteogenic differentiation. The study connects FTO-dependent RNA regulation with stem cell migration, proliferation, osteogenic commitment, and pharmacological inhibition relevant to bone-regeneration research.

• Parathyroid hormone (1-34) (human) in Kidney Models

  2026-10-01

  Use Parathyroid hormone (1-34) (human) as a defined receptor stimulus across bone, calcium, and spatially organized kidney models. This guide connects dose-aware signaling assays with kidney assembloid workflows while separating validated product activity from forward-looking experimental applications.

• Difloxacin HCl: Practical Research Workflows

  2026-09-30

  Difloxacin HCl supports two distinct bench applications: bacterial antimicrobial susceptibility testing and exploratory multidrug resistance reversal studies. This guide converts its DNA gyrase activity, solubility profile, and MRP substrate sensitization potential into practical workflows while using mitotic checkpoint research to sharpen mechanistic assay design.

• Dacarbazine: From DNA Damage to Translation

  2026-09-30

  A thought-leadership guide to using Dacarbazine as both an antineoplastic chemotherapy drug and a translational model of DNA alkylation, with practical advice on assay design, clinical context, supportive care, and reproducible research workflows.

• AM 281: CB1 Cannabinoid Receptor Antagonist

  2026-09-29

  AM 281 enables selective interrogation of CB1 signaling in astrocyte, neuronal survival, and cognition workflows. This guide translates recent TBI findings into practical compound-handling, assay-design, and troubleshooting strategies for memory impairment research and related neuropharmacology studies.

• Dual-Loaded Liposome Encapsulation Efficiency

  2026-09-29

  Tong Yuan and colleagues compared separation strategies for measuring encapsulation efficiency when liposomes contain one hydrophilic and one lipophilic drug. Their validated nanoparticle exclusion HPLC approach enabled simultaneous analysis of both payloads and was more broadly applicable than methods requiring PEGylation or labor-intensive pretreatment.

• 3-Deazaadenosine Hydrochloride in m6A Assays

  2026-09-28

  3-Deazaadenosine hydrochloride is a selective S-adenosylhomocysteine hydrolase inhibitor for interrogating methylation-dependent biology. This guide connects SAHH inhibition with the IGF2BP1–TUBB4B liver-fibrosis model and translates the mechanism into better assay controls and interpretation.

• Difloxacin HCl: Mechanism, Uses, and Benchmarks

  2026-09-28

  Difloxacin HCl is a quinolone antimicrobial antibiotic described as an inhibitor of bacterial DNA gyrase and a reagent for antimicrobial susceptibility testing. Product information also reports multidrug resistance reversal in human neuroblastoma cells, a distinct research finding that should not be interpreted as evidence of clinical efficacy.

8621 records 1/575 page Next 12345 下5页 Last page